NCT00399295View on ClinicalTrials.gov

An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

Not specified

Study Completion Date

June 30, 1997

Conditions
Analgesia
Interventions
DRUG

Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.

All Listed Sponsors
lead

Alza Corporation, DE, USA

INDUSTRY

NCT00399295 - An Open-Label Evaluation of the Independent Effects of Coadministration of a High-Fat Meal and Naltrexone Blockade on the Pharmacokinetic Profile of Dilaudid OROS (Hydromorphone HCI) 16mg | Biotech Hunter | Biotech Hunter